StockData

Kymera Therapeutics vs Arcus Biosciences

KYMR and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KYMR and RCUS compare

Kymera Therapeutics is the larger company, worth 5.0 times as much as Arcus Biosciences ($10.4B against $2.1B).

Kymera Therapeutics grew revenue faster over the last twelve months (134% versus −55.3% for Arcus Biosciences).

Kymera Therapeutics keeps more of each dollar of sales as profit, with a net margin of −342% compared with −393% at Arcus Biosciences.

Kymera Therapeutics scores higher on the StockData Score (9 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKYMRRCUS
Size and price
Market cap$10.4B$2.1B
Share price$121.52$16.39
Change, 1 year87.1%−18.3%
Change, 5 years126%−64.6%
Beta (5Y)0.591.13
Employees238601
StockData Score
Total score9 (better)3
Valuation score00
Growth score12 (better)
Performance score2 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/S101×17.8× (better)
P/B6.4×4.5× (better)
FCF yield−2.8% (better)−22.8%
Fair value$37.15$7.34
Margin of safety−227%−123% (better)
Growth
Revenue growth (TTM)134% (better)−55.3%
Revenue growth, 5Y average2.9%25.9% (better)
Profitability
Gross margin0.00%–
Operating margin−396% (better)−415%
Net margin−342% (better)−393%
FCF margin−283% (better)−406%
Return on equity−27.3% (better)−90.8%
Return on invested capital−59.0%–
Financial health
Debt / equity0.00–
Interest coverage–−44.2×
Current ratio11.13 (better)3.82
Altman Z-score39.62 (better)−0.74
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield–−13.8%
Shareholder yield0.00% (better)−13.8%
Ownership
Held by institutions114%96.3%
Held by insiders38.3%31.7%
Insider net buying, 12 months−$301M−$9.3M (better)
Short interest, % of float16.0%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.